These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36728309)

  • 1. Management of Belantamab Mafodotin-Associated Keratopathy With Rigid Gas-Permeable Corneal Contact Lenses.
    Keye P; Engelhardt M; Wäsch R; Böhringer D; Reinhard T
    Cornea; 2023 Jun; 42(6):744-746. PubMed ID: 36728309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report.
    Marquant K; Quinquenel A; Arndt C; Denoyer A
    J Hematol Oncol; 2021 Oct; 14(1):159. PubMed ID: 34602074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
    Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
    Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma.
    Abeykoon JP; Vaxman J; Patel SV; Kumar S; Malave GC; Young KS; Ailawadhi S; Larsen JT; Dispenzieri A; Muchtar E; Gonsalves WI; Kourelis T; Leung N; Warsame R; Go RS; Bergsagel L; Lacy MQ; Rajkumar SV; Gertz MA; Kapoor P
    Br J Haematol; 2022 Oct; 199(1):95-99. PubMed ID: 35694818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
    Matsumiya W; Karaca I; Ghoraba H; Akhavanrezayat A; Mobasserian A; Hassan M; Regenold J; Yasar C; Liedtke M; Kitazawa K; Nguyen QD
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101133. PubMed ID: 34169181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
    Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
    Gallin V; Nölle B; Schub N; Roider J
    Cornea; 2024 Jun; ():. PubMed ID: 38900711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
    Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
    Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.
    Mickevicius T; Pink AE; Bhogal M; O'Brart D; Robbie SJ
    Cornea; 2023 Apr; 42(4):507-519. PubMed ID: 36525340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
    Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
    Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
    Kurt RA; Gören D; Karadeniz S; Arat M; Sahin A
    Arq Bras Oftalmol; 2022 Nov; 87(4):. PubMed ID: 36350901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
    Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
    Front Oncol; 2021; 11():678634. PubMed ID: 34046363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin].
    Menardais B; Soethoudt M; Espargillière D; Mouriaux F
    J Fr Ophtalmol; 2021 May; 44(5):766-768. PubMed ID: 33454122
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on scleral lenses.
    Jacobs DS
    Curr Opin Ophthalmol; 2008 Jul; 19(4):298-301. PubMed ID: 18545010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contact lenses for the treatment of ocular surface diseases.
    Sharma N; Sah R; Priyadarshini K; Titiyal JS
    Indian J Ophthalmol; 2023 Apr; 71(4):1135-1141. PubMed ID: 37026245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.